eposerin
pfizer italia s.r.l. - ceftizoxima - ceftizoxima
cefodie
mediolanum farmaceutici s.p.a. - cefonicid - cefonicid
monobios
laboratorio farmaceutico c.t. s.r.l. - cefonicid - cefonicid
cefonicid ratiopharm
ratiopharm gmbh - cefonicid - cefonicid
marbocyl bolus
vetoquinol s.a. - marbofloxacina - marbofloxacina - 50 milligrammo (i), marbofloxacina - 50 mg - marbofloxacin
arikayce liposomal
insmed netherlands b.v. - amikacin sulfate - infezioni del tratto respiratorio - antibatterici per uso sistemico, - arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (ntm) lung infections caused by mycobacterium avium complex (mac) in adults with limited treatment options who do not have cystic fibrosis.
mefoxin
i.b.n. savio s.r.l - cefoxitina - cefoxitina
taxime
pharmatex italia s.r.l. - cefotaxima - cefotaxima
ceftriaxone dotopharma
dotopharma ug - ceftriaxone - ceftriaxone
ertapenem sun
sun pharmaceutical industries (europe) b.v. - ertapenem sodico - infezioni batteriche - ertapenem - treatmentertapenem sun is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4. 4 e 5. 1):- intra-abdominal infections- community acquired pneumonia- acute gynaecological infections- diabetic foot infections of the skin and soft tissue (see section 4. 4)preventionertapenem sun is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..